Skip to main content
Premium Trial:

Request an Annual Quote

Wisconsin Blood Supplier Using BioTrove's Genotyping Technology in Donor Matching

NEW YORK (GenomeWeb News) – The BloodCenter of Wisconsin is using BioTrove’s genotyping technology to develop a SNP-based screening tool that will help detect rare blood types and make for better transfusion matches, the company said today.
 
The BloodCenter, which provides blood to over 50 hospitals in Wisconsin, is using BioTrove’s OpenArray SNP platform in research that will allow it to stratify blood donors based on genotypic characteristics, which will improve speed and accuracy of transfusion, the company said.
 
“The need for blood is constant – and for those patients with rare blood types, finding a match can be extremely difficult,” Brad Pietz, director of product development for the diagnostic laboratories of the BloodCenter of Wisconsin, said in a statement.
 
Locating appropriate donors depends on more than matching the common blood type varieties A, B, and O, but it also depends on the specificity of antibodies in the recipient’s blood and antigens that may vary between individuals in the donor group.
 
The BioTrove platform uses through-hole nanoliter fluidics technology to allow researchers to conduct more than 3,000 simultaneous PCR analyses using a metal plate. In addition, the study with the BloodCenter will use chemistries from Applied Biosystems, which inked a genotyping collaboration with BioTrove in November 2007. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more